MedTech IGNITE's ROSTER OF COACHES

Mr. Adams became President of the SOLX division of OccuLogix, Inc. on August 31, 2006 with the acquisition of SOLX, a company he founded in 2000. Mr. Adams has an accomplished history in the ophthalmic industry with more than 25 years experience. Mr. Adams has directed the launch of more than 20 products while holding the position of founder and CEO at several start-up companies, in addition to senior executive positions at a variety of companies including Summit Technology, Allergan Medical Optics, and Humphrey Instruments. He holds a BBA from the University of Georgia and has completed executive leadership courses from Columbia University and the Wharton School of Business. He has served on industry advisory boards for Boston University and Ocular Surgery News International.

Mr. Arnold is a seasoned CEO and serial entrepreneur of medical device and life sciences companies who has raised over $120 million in venture capital, IPO and post IPO financings and achieved considerable returns for VC investors through IPO and acquisition while bringing lifesaving technologies to market. Mr. Arnold advises medical device inventors and entrepreneurs on strategy and is active in company formation, financing and strategic partnerships.

From 2001 through early 2005 he was CEO of CardioFocus where he developed a unique endoscopic catheter for treating atrial fibrillation -- now in human trials. In the Spring of 2005 he hired a new CEO and remained as Chairman.

Prior to that in 1993 he founded Cambridge Heart, Inc. (NASDAQ: CAMH), a supplier of cardiology diagnostic equipment, which he took public in a Goldman Sachs led IPO in 1996. He hired a CEO in 2001 and remained as Chairman.

Prior to Cambridge Heart he was CEO of Molecular Simulations, Inc., a $100 MM supplier of software for drug design now called Accelrys (NASDAQ: ACCL). He grew MSI from $10 to $25 MM in two years, then purchased its competitor, BioSym, was sold to Pharmacopeia for $200+ MM and later spun out as Accelrys.

In his early career Mr. Arnold held senior R & D and marketing positions for Becton Dickinson and ran the instrumentation group for medical equipment supplier Datascope Corp during a period of rapid growth from $14 to $40 MM in revenues.

Mr. Arnold is a guest lecturer at the MIT Entrepreneurship Center and Sloan School, a mentor to early stage companies through the MIT Venture Mentoring Society and is on the grant review board at the MIT Deshpande Center. He was formerly Chairman of the Board of the Greater Boston Chapter of the American Heart Association.

Mr. Arnold received a BSEE from MIT in 1972.

Dr. Davison is a serial entrepreneur and executive with 35 years of experience in the medical device industry. He was the co-founder of four medical device companies and he has held executive management positions in product development, business development, clinical research, sales and marketing for major medical device companies including Sherwood Medical (now Tyco International), Intermedics, Pfizer, and Ethicon Endosurgery (J & J). During the past twenty years, Dr. Davison has led three start-up companies during the difficult early growth stages from technology and product conception through clinical validation and market launch.

Dr. Davison began his career in the medical device industry in 1972 at the International Liquid Crystal Company (ILIXCO) which was founded by his graduate research advisor and inventor of the modern liquid crystal display, Dr. James Fergason. At ILIXCO, Dr. Davison formed a biomedical subsidiary, Liquid Crystal Biosystems and continued his doctoral dissertation research to develop the medical applications of temperature sensitive liquid crystals used for thermography and temperature measurement. Dr. Davison left ILIXCO in 1975 and co-founded Biosynergy to develop medical products with temperature sensitive liquid crystals that were used in IV therapy, phlebotomy, anesthesiology and blood banking.

Dr. Davison joined Sherwood Medical in 1980 as a product manager for cardiothoracic products including chest drainage and perfusion catheters. As a group product manager in 1983, his team launched 40 new products for general surgery, cardiothoracic surgery and intravenous therapy. That led to his promotion to Director of Corporate New Business and Product Development. Dr. Davison left Sherwood in 1986 to join Intermedics Infusaid (technology acquired by Arrow Intl.) as Vice President Sales, Marketing and Clinical Research. Infusaid developed the first implantable drug delivery pump and the first vascular access port.

Dr. Davison left Infusaid in 1988 to continue his career as a medical device entrepreneur when he co-founded UltraCision. As President of UltraCision, Dr. Davison led the development of the Harmonic Scalpel® and Coagulating Shears. UltraCision and the Harmonic Scalpel were sold to Ethicon Endosurgery, a Johnson & Johnson company in late 1995. Today, the Harmonic Scalpel and Shears are the gold standard in laparoscopic surgery with sales exceeding $500 million worldwide. The Harmonic line is the largest medical device brand at J & J.

Dr. Davison co-founded Endius Incorporated in 1996 where he was the Chief Executive Officer. Endius developed and commercialized the first endoscopic spine fusion technology and surgical procedure. The Endius FlexPosure spinal access and Atavi minimal invasive instruments enable surgeons to perform spinal fusions with significantly less post operative pain, faster recovery and improved outcomes. Developments at Endius are changing the way spine surgeons approach spine surgery. In February 2007, Zimmer Holdings announced its intention to acquire Endius as a part of their strategy to be a leader in less traumatic and motion preservation spine surgery.

Dr. Davison left Endius in 2002 to revitalize Sontra Medical Corporation where he was joined by many of the UltraCision management and development team. Sontra is a transdermal science company with product platforms that enable continuous transdermal diagnostic monitoring and drug delivery. Sontra was the first to recognize the unmet market need for a continuous glucose monitor in critical care. Sontra's Symphony continuous transdermal glucose monitor is expected to be the most important advance in critical care patient monitoring since Nelcor (Tyco) introduced pulse oximetry in the early 1980's.

Dr. Davison left Sontra in January, 2007 and founded MedTech Innovations, LLC to help scientists and entrepreneurs bridge the gap between medical technology and business. Major clients include BTG plc, a British medical technology development company, and Ethicon Endosurgery (Johnson & Johnson).

Dr. Davison has served on the Boards of numerous private companies as CEO and COO (Biosynergy, UltraCision, Endius) and public companies including Sontra and MedChem Products. Sontra was listed on NASDAQ and MedChem was on the New York Stock Exchange. MedChem was acquired by CR Bard in late 1995.

Dr. Davison holds over 20 patents on medical device technologies and products including liquid crystal devices, cardio-pulmonary perfusion catheters, thoracic drainage, the Harmonic Scalpel and the Endius Atavi® minimally invasive instruments and FlexPosure® access device.

Education:
Kent State University, B.A. Major Biology, Minor Chemistry; M.S. Major Physiology; Ph.D. Major Mammalian Physiology, Minors Biomed Eng. & Zoology

Mr. Dempsey, co-founder and Chief Technology Officer at Radianse, Inc., has been working in the field of wireless medical communications for more than 20 years. Prior to co-founding Radianse, he worked as a technical strategist for wireless solutions at Hewlett-Packard/Agilent Technologies (now Philips Medical Systems). He has helped to develop and introduce dozens of successful products, holds six patents in wireless medical device communications and has six more pending for indoor positioning. He served on the American Hospital Association's taskforce on medical telemetry, acted as chairman of the Service Rules Committee and vice-chair of the frequency allocation committee. He received a special citation from the FDA for "exceptional initiative and leadership to protect the public health." He has a BSEE from The University of Michigan.

Dr. Freeman was president/CEO of HydroCision, Inc., a fluidjet-based medical device company, from 1996 to 2002, when he retired, remaining on the board. From 1996 until 2000, he was also Chairman, CEO and a Director of RadioMed Corporation, a developer of medical devices incorporating radioisotopes for inhibition of cellular proliferation.

RadioMed was acquired by IBA in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, an investment banking firm specializing in the healthcare field. Previously, he was president/CEO of Intra-Sonix, Inc. and Xenotech Laboratories, both medical device companies. Still earlier, he was President of Davol, Inc., which was acquired by C. R. Bard, after which he served as a Group Vice President of Bard. Before Davol, he was President of Friesen International, a hospital design firm owned by American Medical International. He was Director, New Business Development for Union Carbide Corp., where he was also General Manager of its clinical diagnostics, radiopharmaceuticals and imaging buesinesses. Dr. Freeman's early career was as a scientist at Union Carbide.

He holds an ScB from Brown University and a PhD in chemistry from the University of Maryland, and did post-doctoral research in physics at Duke. He is inventor or co-inventor on some 19 US patents. He attended the Harvard Business School Advanced Management Program and has been a Director of numerous companies, public and private, in the healthcare field. He is currently on the board of PhotoBioChem (Leiden, NL), SemiNex (Mass), Medical Record Bank (Mass), Electrolyzer Corporation (Mass) and Pluromed Corporation (Mass) as well as HydroCision. He holds investments in those companies, in addition to 6 other early-stage ventures.

Dr. Gozani founded Neurometrix in 1996 and currently serves as Chairman of the company’s board of directors and as President and Chief Executive Officer. Since founding the company in 1996, Dr. Gozani has served in a number of positions at the company including Chairman, President and Chief Executive Officer.

Prior to forming Neurometrix, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry.

Dr. Gozani holds a B.A. degree in Computer Science, an M.S. degree in Biomedical Engineering and a Ph.D. in Neurobiology from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T.

Mr. McCarty, President of Hawaii Medical, has developed and marketed products for premature babies for more than 20 years. Past president and founder of Children’s Medical Ventures, he helped pioneer products to implement Developmental Care in the NICU. For over 25 years, Mr. McCarty has been involved in the development and commercialization of medical devices. His basic research includes work at Boston Children’s Hospital in blood separation technologies related to Thalassemia and other blood disorders. Currently, Read travels all over the US to meet with clinicians to discover needs and product improvements for the NICU.

Prior to becoming CEO of GI Dynamics, Mr. Randle was an Entrepreneur In Residence at Advanced Technology Ventures. Prior to ATV, he was the president and CEO at ACT Medical, Inc., where he was responsible for developing and executing a new strategy that resulted in the sale of the company to MedSource Technologies, Inc. in 2001. Prior to ACT Medical, Mr. Randle was a corporate officer at Allegiance Healthcare Corporation, where he helped plan and execute the spinoff from Baxter International. Previously, he spent 10 years with Baxter in various senior management positions and was responsible for launching the world’s first needleless IV system.

Mr. Randle earned an MBA from The Kellogg Graduate School of Management at Northwestern University and a BS in Mechanical Engineering from Cornell University.

Previously CEO of Confluent Surgical, Dr. Sawhney is one of the inventors of the hydrogel technology, which formed the core of Confluent's technology platform. His inventions have formed the basis for the founding of several medical device and biotechnology companies and their products. In addition, other companies that are pursuing technologies that have been co-invented by Dr. Sawhney include Access Closure, Inc. (ACI), Novacell, and Azopax. Dr. Sawhney holds over 55 patents and has authored over 100 publications and scientific abstracts. Prior to co-founding Confluent, Dr. Sawhney was Director and Technology Founder at Focal, Inc. (acquired by Genzyme). In addition to Confluent, he serves on the board of MarketRx Inc. (an Incept company specializing in sales and marketing effectiveness, planning, and analytical products and services) as well as ACI. He currently serves as CEO of I-Therapeutix, a start-up company focusing on in-situ formed hydrogel technologies for ophthalmology.